Systemic Delivery of Folate-PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability for in Vivo Gene Silencing in Leukemia

Dian Jang Lee, Eva Kessel, Taavi Lehto, Xueying Liu, Naoto Yoshinaga, Kärt Padari, Ying Chen Chen, Susanne Kempter, Satoshi Uchida, Joachim O. Rädler, Margus Pooga, Ming Thau Sheu, Kazunori Kataoka, Ernst Wagner

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Protection of small interfering RNA (siRNA) against degradation and targeted delivery across the plasma and endosomal membranes to the final site of RNA interference (RNAi) are major aims for the development of siRNA therapeutics. Targeting for folate receptor (FR)-expressing tumors, we optimized siRNA polyplexes by coformulating a folate-PEG-oligoaminoamide (for surface shielding and targeting) with one of three lipo-oligoaminoamides (optionally tyrosine-modified, for optimizing stability and size) to generate ∼100 nm targeted lipopolyplexes (TLPs), which self-stabilize by cysteine disulfide cross-links. To better understand parameters for improved tumor-directed gene silencing, we analyzed intracellular distribution and siRNA release kinetics. FR-mediated endocytosis and endosomal escape of TLPs was confirmed by immuno-TEM. We monitored colocalization of TLPs with endosomes and lysosomes, and onset of siRNA release by time-lapse confocal microscopy; analyzed intracellular stability by FRET using double-labeled siRNA; and correlated results with knockdown of eGFPLuc protein and EG5 mRNA expression. The most potent formulation, TLP1, containing lipopolyplex-stabilizing tyrosine trimers, was found to unpack siRNA in sustained manner with up to 5-fold higher intracellular siRNA stability after 4 h compared to other TLPs. Unexpectedly, data indicated that intracellular siRNA stability instead of an early endosomal exit dominate as a deciding factor for silencing efficiency of TLPs. After i.v. administration in a subcutaneous leukemia mouse model, TLP1 exhibited ligand-dependent tumoral siRNA retention, resulting in 65% EG5 gene silencing at mRNA level without detectable adverse effects. In sum, tyrosine-modified TLP1 conveys superior protection of siRNA for an effective tumor-targeted delivery and RNAi in vivo.

Original languageEnglish
Pages (from-to)2393-2409
Number of pages17
JournalBioconjugate Chemistry
Volume28
Issue number9
DOIs
Publication statusPublished - Sep 20 2017

Fingerprint

Gene Silencing
RNA
Small Interfering RNA
Polyethylene glycols
Leukemia
Genes
RNA Stability
Tyrosine
Tumors
RNA Interference
Folic Acid
poly(ethylene glycol)-folate
Neoplasms
Messenger RNA
Confocal microscopy
Endosomes
Endocytosis
Lysosomes
Confocal Microscopy
Disulfides

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry

Cite this

Systemic Delivery of Folate-PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability for in Vivo Gene Silencing in Leukemia. / Lee, Dian Jang; Kessel, Eva; Lehto, Taavi; Liu, Xueying; Yoshinaga, Naoto; Padari, Kärt; Chen, Ying Chen; Kempter, Susanne; Uchida, Satoshi; Rädler, Joachim O.; Pooga, Margus; Sheu, Ming Thau; Kataoka, Kazunori; Wagner, Ernst.

In: Bioconjugate Chemistry, Vol. 28, No. 9, 20.09.2017, p. 2393-2409.

Research output: Contribution to journalArticle

Lee, DJ, Kessel, E, Lehto, T, Liu, X, Yoshinaga, N, Padari, K, Chen, YC, Kempter, S, Uchida, S, Rädler, JO, Pooga, M, Sheu, MT, Kataoka, K & Wagner, E 2017, 'Systemic Delivery of Folate-PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability for in Vivo Gene Silencing in Leukemia', Bioconjugate Chemistry, vol. 28, no. 9, pp. 2393-2409. https://doi.org/10.1021/acs.bioconjchem.7b00383
Lee, Dian Jang ; Kessel, Eva ; Lehto, Taavi ; Liu, Xueying ; Yoshinaga, Naoto ; Padari, Kärt ; Chen, Ying Chen ; Kempter, Susanne ; Uchida, Satoshi ; Rädler, Joachim O. ; Pooga, Margus ; Sheu, Ming Thau ; Kataoka, Kazunori ; Wagner, Ernst. / Systemic Delivery of Folate-PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability for in Vivo Gene Silencing in Leukemia. In: Bioconjugate Chemistry. 2017 ; Vol. 28, No. 9. pp. 2393-2409.
@article{08fd87e1a14c49ddbfdf95b91c5ae678,
title = "Systemic Delivery of Folate-PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability for in Vivo Gene Silencing in Leukemia",
abstract = "Protection of small interfering RNA (siRNA) against degradation and targeted delivery across the plasma and endosomal membranes to the final site of RNA interference (RNAi) are major aims for the development of siRNA therapeutics. Targeting for folate receptor (FR)-expressing tumors, we optimized siRNA polyplexes by coformulating a folate-PEG-oligoaminoamide (for surface shielding and targeting) with one of three lipo-oligoaminoamides (optionally tyrosine-modified, for optimizing stability and size) to generate ∼100 nm targeted lipopolyplexes (TLPs), which self-stabilize by cysteine disulfide cross-links. To better understand parameters for improved tumor-directed gene silencing, we analyzed intracellular distribution and siRNA release kinetics. FR-mediated endocytosis and endosomal escape of TLPs was confirmed by immuno-TEM. We monitored colocalization of TLPs with endosomes and lysosomes, and onset of siRNA release by time-lapse confocal microscopy; analyzed intracellular stability by FRET using double-labeled siRNA; and correlated results with knockdown of eGFPLuc protein and EG5 mRNA expression. The most potent formulation, TLP1, containing lipopolyplex-stabilizing tyrosine trimers, was found to unpack siRNA in sustained manner with up to 5-fold higher intracellular siRNA stability after 4 h compared to other TLPs. Unexpectedly, data indicated that intracellular siRNA stability instead of an early endosomal exit dominate as a deciding factor for silencing efficiency of TLPs. After i.v. administration in a subcutaneous leukemia mouse model, TLP1 exhibited ligand-dependent tumoral siRNA retention, resulting in 65{\%} EG5 gene silencing at mRNA level without detectable adverse effects. In sum, tyrosine-modified TLP1 conveys superior protection of siRNA for an effective tumor-targeted delivery and RNAi in vivo.",
author = "Lee, {Dian Jang} and Eva Kessel and Taavi Lehto and Xueying Liu and Naoto Yoshinaga and K{\"a}rt Padari and Chen, {Ying Chen} and Susanne Kempter and Satoshi Uchida and R{\"a}dler, {Joachim O.} and Margus Pooga and Sheu, {Ming Thau} and Kazunori Kataoka and Ernst Wagner",
year = "2017",
month = "9",
day = "20",
doi = "10.1021/acs.bioconjchem.7b00383",
language = "English",
volume = "28",
pages = "2393--2409",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Systemic Delivery of Folate-PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability for in Vivo Gene Silencing in Leukemia

AU - Lee, Dian Jang

AU - Kessel, Eva

AU - Lehto, Taavi

AU - Liu, Xueying

AU - Yoshinaga, Naoto

AU - Padari, Kärt

AU - Chen, Ying Chen

AU - Kempter, Susanne

AU - Uchida, Satoshi

AU - Rädler, Joachim O.

AU - Pooga, Margus

AU - Sheu, Ming Thau

AU - Kataoka, Kazunori

AU - Wagner, Ernst

PY - 2017/9/20

Y1 - 2017/9/20

N2 - Protection of small interfering RNA (siRNA) against degradation and targeted delivery across the plasma and endosomal membranes to the final site of RNA interference (RNAi) are major aims for the development of siRNA therapeutics. Targeting for folate receptor (FR)-expressing tumors, we optimized siRNA polyplexes by coformulating a folate-PEG-oligoaminoamide (for surface shielding and targeting) with one of three lipo-oligoaminoamides (optionally tyrosine-modified, for optimizing stability and size) to generate ∼100 nm targeted lipopolyplexes (TLPs), which self-stabilize by cysteine disulfide cross-links. To better understand parameters for improved tumor-directed gene silencing, we analyzed intracellular distribution and siRNA release kinetics. FR-mediated endocytosis and endosomal escape of TLPs was confirmed by immuno-TEM. We monitored colocalization of TLPs with endosomes and lysosomes, and onset of siRNA release by time-lapse confocal microscopy; analyzed intracellular stability by FRET using double-labeled siRNA; and correlated results with knockdown of eGFPLuc protein and EG5 mRNA expression. The most potent formulation, TLP1, containing lipopolyplex-stabilizing tyrosine trimers, was found to unpack siRNA in sustained manner with up to 5-fold higher intracellular siRNA stability after 4 h compared to other TLPs. Unexpectedly, data indicated that intracellular siRNA stability instead of an early endosomal exit dominate as a deciding factor for silencing efficiency of TLPs. After i.v. administration in a subcutaneous leukemia mouse model, TLP1 exhibited ligand-dependent tumoral siRNA retention, resulting in 65% EG5 gene silencing at mRNA level without detectable adverse effects. In sum, tyrosine-modified TLP1 conveys superior protection of siRNA for an effective tumor-targeted delivery and RNAi in vivo.

AB - Protection of small interfering RNA (siRNA) against degradation and targeted delivery across the plasma and endosomal membranes to the final site of RNA interference (RNAi) are major aims for the development of siRNA therapeutics. Targeting for folate receptor (FR)-expressing tumors, we optimized siRNA polyplexes by coformulating a folate-PEG-oligoaminoamide (for surface shielding and targeting) with one of three lipo-oligoaminoamides (optionally tyrosine-modified, for optimizing stability and size) to generate ∼100 nm targeted lipopolyplexes (TLPs), which self-stabilize by cysteine disulfide cross-links. To better understand parameters for improved tumor-directed gene silencing, we analyzed intracellular distribution and siRNA release kinetics. FR-mediated endocytosis and endosomal escape of TLPs was confirmed by immuno-TEM. We monitored colocalization of TLPs with endosomes and lysosomes, and onset of siRNA release by time-lapse confocal microscopy; analyzed intracellular stability by FRET using double-labeled siRNA; and correlated results with knockdown of eGFPLuc protein and EG5 mRNA expression. The most potent formulation, TLP1, containing lipopolyplex-stabilizing tyrosine trimers, was found to unpack siRNA in sustained manner with up to 5-fold higher intracellular siRNA stability after 4 h compared to other TLPs. Unexpectedly, data indicated that intracellular siRNA stability instead of an early endosomal exit dominate as a deciding factor for silencing efficiency of TLPs. After i.v. administration in a subcutaneous leukemia mouse model, TLP1 exhibited ligand-dependent tumoral siRNA retention, resulting in 65% EG5 gene silencing at mRNA level without detectable adverse effects. In sum, tyrosine-modified TLP1 conveys superior protection of siRNA for an effective tumor-targeted delivery and RNAi in vivo.

UR - http://www.scopus.com/inward/record.url?scp=85029610594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029610594&partnerID=8YFLogxK

U2 - 10.1021/acs.bioconjchem.7b00383

DO - 10.1021/acs.bioconjchem.7b00383

M3 - Article

VL - 28

SP - 2393

EP - 2409

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 9

ER -